Vicapsys Life Sciences Stock Price, News & Analysis (OTCMKTS:VICP) $2.75 0.00 (0.00%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$2.75▼$2.7550-Day Range$1.00▼$3.0052-Week Range$1.03▼$3.00VolumeN/AAverage Volume12 shsMarket Capitalization$88.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsStock AnalysisChartEarningsFinancialsHeadlinesSEC Filings About Vicapsys Life Sciences Stock (OTCMKTS:VICP)Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Cumming, Georgia.Read More VICP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VICP Stock News HeadlinesNovember 4, 2023 | morningstar.comAnavex Life Sciences Corp AVXLAugust 9, 2023 | finance.yahoo.comVICP - Vicapsys Life Sciences, Inc.December 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.July 3, 2023 | msn.comViCapsys files for Nasdaq uplisting, $8M public offeringFebruary 19, 2023 | benzinga.comGlobal Life Science Tools Strategic Business Report 2023: Rapid Growth in Biopharma Industry and Rising Investments in R&D to Boost Market ProspectsSeptember 29, 2022 | finance.yahoo.comViCapsys Life Sciences Appoints Three New Board MembersApril 18, 2022 | finance.yahoo.comViCapsys Life Sciences Appoints Federico Pier as Permanent Chief Executive OfficerSee More Headlines Receive VICP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vicapsys Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:VICP CUSIPN/A CIK1468639 Webvicapsys.com Phone(972) 891-8033FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-990,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-598.64% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-68.75Miscellaneous Outstanding Shares32,071,000Free Float30,153,000Market Cap$88.20 million OptionableNot Optionable Beta-5.17 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Federico Pier (Age 55)CEO, Executive Chairman & Interim President Comp: $120kMr. Jeffery Wright CPA (Age 40)CPA, Chief Financial Officer Comp: $90kDr. Mark C. Poznansky M.D.Ph.D., Chief Scientist Advisor & FounderKey CompetitorsEnvivaNYSE:EVANobility HomesOTCMKTS:NOBHM-tron IndustriesNYSEAMERICAN:MPTIGlatfelterNYSE:GLTGeneral Enterprise VenturesOTCMKTS:GEVIView All Competitors VICP Stock Analysis - Frequently Asked Questions How have VICP shares performed in 2023? Vicapsys Life Sciences' stock was trading at $1.00 at the beginning of the year. Since then, VICP stock has increased by 175.0% and is now trading at $2.75. View the best growth stocks for 2023 here. How were Vicapsys Life Sciences' earnings last quarter? Vicapsys Life Sciences, Inc. (OTCMKTS:VICP) released its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of Vicapsys Life Sciences? Shares of VICP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:VICP) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vicapsys Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.